Streetbeat News

Products Services

AAPL

DIS

NFLX

Apple Inc. has announced an immediate price increase for its prime services, including Apple TV+, Arcade, and Apple One. The monthly subscription price for Apple TV+ has been raised from $6.99 to $9.99, and the yearly plan has increased from $69 to $99. The bundled package Apple One is now priced at $37.95 per month. Apple’s Arcade and News+ monthly subscriptions will now cost $6.99 and $12.99, respectively. These services generated $21.21 billion in Apple's fiscal third quarter, making it Apple’s second-largest business after the iPhone.

Portfolio Pulse from Benzinga Neuro

October 26, 2023 | 1:24 am

VRNOF

Verano Holdings Corp. has launched Savvy Threads, a limited-edition streetwear and e-commerce platform that celebrates the company’s cannabis brand imagery. The collection includes exclusive apparel inspired by popular Verano genetics. The launch of Savvy Threads complements the expanding Savvy cannabis product portfolio. Verano’s shares traded 2.9668% lower at $4.0948 per share after the market close on Tuesday.

Portfolio Pulse from Jelena Martinovic

October 25, 2023 | 11:38 pm

MSFT

Microsoft Corp (NASDAQ:MSFT) celebrates the 40th anniversary of its key product, Microsoft Word, which was first released on Oct. 25, 1983. The company highlighted the product's evolution and its future plans, including the integration of artificial intelligence in its development. The company also emphasized its commitment to improving Word's efficiency and co-creation capabilities.

Portfolio Pulse from Chris Katje

October 25, 2023 | 10:40 pm

MA

V

Mastercard (NYSE:MA) and MoonPay have announced a partnership to explore how Web3 tools can enhance experiential marketing and connect with consumers. MoonPay will use Mastercard's Crypto Credential system and integrate payments technology like Mastercard Send and Click to Pay. Otherlife, MoonPay’s subsidiary, will play a key role in the partnership. Visa Inc (NYSE:V) has also been active in the Web3 space, extending its stablecoin settlement capabilities to the Solana blockchain and partnering with Bitcoin rewards app Fold.

Portfolio Pulse from Khyathi Dalal

October 25, 2023 | 10:19 pm

META

Meta's CFO has announced plans to allocate more headcount towards AI, infrastructure, Reality Labs, monetization, and regulatory needs, according to Reuters.

Portfolio Pulse from Charles Gross

October 25, 2023 | 9:32 pm

BIIB

ESALY

Eisai has presented new interim study results for its investigational subcutaneous formulation LEQEMBI, which is being studied for use in early Alzheimer's disease. The formulation has shown to clear 14% more plaque than IV, with pharmacokinetics 11% higher and similar ARIA rates to IV. Additionally, 76% of patients showed no decline and 60% showed clinical improvement at 18 months in a low-Tau subpopulation in an additional analysis of Clarity AD.

Portfolio Pulse from Benzinga Newsdesk

October 25, 2023 | 9:28 pm

RMBS

Rambus Inc. (NASDAQ:RMBS) has announced that its HBM3 Memory Controller IP now delivers up to 9.6 Gigabits per second (Gbps) performance, a 50% increase over the HBM3 Gen1 data rate of 6.4 Gbps. This enhancement supports the continued evolution of the HBM3 standard and enables a total memory throughput of over 1.2 Terabytes per second (TB/s) for training of recommender systems, generative AI and other demanding data center workloads.

Portfolio Pulse from Benzinga Newsdesk

October 25, 2023 | 9:28 pm

ALNY

Alnylam Pharmaceuticals has published the results of its APOLLO-B Phase 3 study of Patisiran in patients with Cardiomyopathy of ATTR Amyloidosis in the New England Journal of Medicine. The results of the study could have significant implications for the company's future.

Portfolio Pulse from Benzinga Newsdesk

October 25, 2023 | 9:21 pm

OPK

OPKO Health, Inc. (NASDAQ:OPK) will present new clinical data on RAYALDEE, an extended-release calcifediol, at the American Society of Nephrology Kidney Week in November 2023. The data will demonstrate that RAYALDEE effectively raises serum levels of 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D in non-dialysis patients with secondary hyperparathyroidism, making it an alternative to vitamin D hormone therapies. The data also support early initiation of treatment with RAYALDEE to delay disease progression.

Portfolio Pulse from Benzinga Newsdesk

October 25, 2023 | 9:19 pm

LIAN

LianBio (NASDAQ:LIAN) has presented efficacy and safety data from a Phase 2a study of infigratinib in Chinese patients with advanced gastric cancer at the ESMO Congress 2023. The study showed a confirmed objective response rate of 23.8% and a disease control rate of 76.2%. The drug was well tolerated with no treatment-related adverse events leading to dose discontinuation, death, or drug-induced liver injury. Infigratinib has received Breakthrough Therapy Designation from the China National Medical Products Administration for the treatment of gastric cancer.

Portfolio Pulse from Benzinga Newsdesk

October 25, 2023 | 9:00 pm